HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Diel, R. Articles by Zellweger, J-P. Search for Related Content PubMed PubMed Citation Articles by Diel, R. Articles by Zellweger, J-P.

Cost-effectiveness of interferon- release assay testing for the treatment of latent tuberculosis

¹ School of Public Health, University of Düsseldorf, Germany, ² Oxford Immunotec, Oxford, UK, ³ University Medical Policlinic, Lausanne, Switzerland.

CORRESPONDENCE: R. Diel, School of Public Health, c/o Institute for Medical Sociology, Heinrich Heine University, Post box 101007, D-40001 Düsseldorf, Germany. Fax: 49 40427907185. E-mail: Roland.Diel{at}uni-duesseldorf.de

Keywords: Cost-effectiveness, interferon- release assay, latent tuberculosis infection, latent tuberculosis infection treatment, tuberculosis

Received: November 7, 2006
Accepted April 19, 2007

The aim of the present study was to assess the cost-effectiveness of the new T-SPOT.TB assay versus the tuberculin skin test (TST) for screening contacts for latent tuberculosis (TB) infection in Switzerland.

Health and economic outcomes of isoniazid treatment of 20- and 40-yr-old close contacts were compared in a Markov model over a 20-yr period following screening with TST only (at three cut-off values) and T-SPOT.TB alone or in combination with the TST.

T-SPOT.TB-based treatment was cost-effective at \#8342;11,621 and \#8342;23,692 per life-year-gained (LYG) in the younger and older age group, respectively. No TST-based programmes were cost-effective, except at a 15-mm cut-off in the younger group only, where the cost-effectiveness (\#8342;26,451·LYG^–1) fell just below the willingness-to-pay threshold. Combination of the TST with T-SPOT.TB slightly reduced the total cost compared with the T-SPOT.TB alone by 4.4 and 5.0% in the younger and older groups respectively. The number of contacts treated to avoid one case of TB decreased from 50 (95% confidence interval 32–106) with the TST (10-mm cut-off) to 18 (95%CI 11–43) if T-SPOT.TB was used.

Using T-SPOT.TB alone or in combination with the tuberculin skin test for screening of close contacts before latent tuberculosis infection treatment is highly cost-effective in reducing the disease burden of tuberculosis.

This article has been cited by other articles:

				B. Chikura, V. Sadananda, and M. Usman-Saeed Comment on: Screening for Mycobacterium tuberculosis prior to anti-TNF therapy--an audit of impact of the British Thoracic Society guidelines on rheumatology practice in an area of low Mycobacterium tuberculosis prevalence Rheumatology, June 30, 2009; (2009) kep181v1. [Full Text] [PDF]

				R. Diel Predictive Value of the Tuberculin Skin Test and the QuantiFERON-TB Gold In-Tube Assay for the Development of Active Tuberculosis Disease Am. J. Respir. Crit. Care Med., December 15, 2008; 178(12): 1282 - 1282. [Full Text] [PDF]

				S. G. Rhodes, T. Gruffydd-Jones, D. Gunn-Moore, and K. Jahans Interferon-{gamma} test for feline tuberculosis Vet Rec., April 5, 2008; 162(14): 453 - 454. [Full Text] [PDF]

				D. Brodie, D. J. Lederer, J. S. Gallardo, S. H. Trivedi, J. N. Burzynski, and N. W. Schluger Use of an Interferon-{gamma} Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients Chest, April 1, 2008; 133(4): 869 - 874. [Abstract] [Full Text] [PDF]